The association between telomerase, p53, and clinical staging in colorectal cancer

Am J Surg. 1998 May;175(5):364-6. doi: 10.1016/s0002-9610(98)00057-9.

Abstract

Background: A proposed etiology of tumor activation involves p53 mutations while telomerase may serve as a key enzyme for maintenance of tumor cell proliferation.

Methods: Telomerase activity levels were measured in colorectal adenocarcinomas and corresponding normal tissue using a modified telomeric repeat amplification protocol, and p53 mutations were identified using immunohistochemical staining. Results were compared with staging data using regression analysis.

Results: Telomerase activity was present in 23 of 23 (100%) of the tumors and only 2 (9%) of normal specimens (P <0.0001). The p53 mutations were present in 18 of 23 (78%) of the tumors. No significant correlation between p53 mutations, telomerase activity levels, and staging was found.

Conclusions: Telomerase activity in 100% of the tumors suggests telomerase activation is a universal event in colorectal tumor progression; however, telomerase activity appears to be independent of p53 mutations and clinical staging.

Publication types

  • Comparative Study
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Adenocarcinoma / diagnosis*
  • Adenocarcinoma / genetics
  • Adenocarcinoma / pathology
  • Aged
  • Base Sequence
  • Biomarkers, Tumor / analysis*
  • Biomarkers, Tumor / genetics
  • Clinical Enzyme Tests* / methods
  • Colorectal Neoplasms / diagnosis*
  • Colorectal Neoplasms / genetics
  • Colorectal Neoplasms / pathology
  • Female
  • Humans
  • Immunohistochemistry
  • Male
  • Molecular Sequence Data
  • Mutation
  • Neoplasm Staging
  • Prospective Studies
  • Regression Analysis
  • Repetitive Sequences, Nucleic Acid
  • Telomerase / analysis*
  • Telomerase / genetics
  • Tumor Suppressor Protein p53 / analysis*
  • Tumor Suppressor Protein p53 / genetics

Substances

  • Biomarkers, Tumor
  • Tumor Suppressor Protein p53
  • Telomerase